Literature DB >> 11953466

Non-cytotoxic inhibition of HIV-1 infection by unstimulated CD8+ T lymphocytes from HIV-exposed-uninfected individuals.

Lucinda Furci1, Lucia Lopalco, Patrizia Loverro, Marina Sinnone, Giuseppe Tambussi, Adriano Lazzarin, Paolo Lusso.   

Abstract

OBJECTIVES: Some individuals remain uninfected despite repeated exposure to HIV-1 [exposed-uninfected (EU)]. In addition to genetic factors, acquired immune responses elicited by repeated exposure to HIV antigens may contribute to protection. We investigated the ability of unstimulated CD8+ T lymphocytes from EU individuals to inhibit HIV-1 infection.
METHODS: Peripheral blood CD8+ T lymphocytes from a well-characterized cohort of 16 HIV-1-discordant monogamous heterosexual couples were tested for their suppressive activity against HIV-1 strains displaying different coreceptor usage (R5, X4, X4R5). To evaluate the in vivo functional competence of CD8+ T cells, no ex vivo activatory stimuli were used prior to cocultivation with infected CD4+ T cells. In some experiments, a semi-permeable membrane was used to separate CD4+ and CD8+ T cells.
RESULTS: Unstimulated CD8+ T cells from all but one of the EU individuals analysed effectively inhibited the growth of all HIV-1 strains, regardless of their coreceptor usage, with a mean potency similar to that of asymptomatic HIV-infected patients. The HIV-inhibitory activity persisted for a long time after ceasing high-risk sexual behaviour, although a moderate decline was observed starting 4 years after the last risk episode. Transwell culture experiments showed that soluble factors are involved in CD8-mediated viral suppression, although the activity was higher when cell-to-cell contact was allowed.
CONCLUSIONS: These data demonstrate that CD8+ T cells from EU individuals exert a strong, broad-spectrum HIV-suppressive activity, suggesting a role of non-cytotoxic antiviral mechanisms in resistance to HIV-1 infection.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11953466     DOI: 10.1097/00002030-200205030-00006

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  5 in total

Review 1.  Weighing the Evidence of Efficacy of Oral PrEP for HIV Prevention in Women in Southern Africa.

Authors:  Holly Janes; Lawrence Corey; Gita Ramjee; Lindsay N Carpp; Carl Lombard; Myron S Cohen; Peter B Gilbert; Glenda E Gray
Journal:  AIDS Res Hum Retroviruses       Date:  2018-06-19       Impact factor: 2.205

Review 2.  HIV and the chemokine system: 10 years later.

Authors:  Paolo Lusso
Journal:  EMBO J       Date:  2006-01-26       Impact factor: 11.598

3.  Potentially exposed but uninfected individuals produce cytotoxic and polyfunctional human immunodeficiency virus type 1-specific CD8(+) T-cell responses which can be defined to the epitope level.

Authors:  A L Erickson; C B Willberg; V McMahan; A Liu; S P Buchbinder; L A Grohskopf; R M Grant; D F Nixon
Journal:  Clin Vaccine Immunol       Date:  2008-09-24

4.  CCR5 expression, haplotype and immune activation in protection from infection in HIV-exposed uninfected individuals in HIV-serodiscordant relationships.

Authors:  Shameem Z Jaumdally; Anabela Picton; Caroline T Tiemessen; Maria Paximadis; Heather B Jaspan; Hoyam Gamieldien; Lindi Masson; David Coetzee; Anna-Lise Williamson; Francesca Little; Pamela P Gumbi; Jo-Ann S Passmore
Journal:  Immunology       Date:  2017-05-24       Impact factor: 7.397

5.  Deciphering the Role of Mucosal Immune Responses and the Cervicovaginal Microbiome in Resistance to HIV Infection in HIV-Exposed Seronegative (HESN) Women.

Authors:  Sivasankaran Munusamy Ponnan; Kannan Thiruvengadam; Chaitanya Tellapragada; Anoop T Ambikan; Aswathy Narayanan; Sujitha Kathirvel; Manikannan Mathayan; Janani Shankar; Akshaya Rajaraman; Mehar Afshan Amanulla; Thongadi Ramesh Dinesha; Selvamuthu Poongulali; Shanmugam Saravanan; Kailapuri Gangatharan Murugavel; Soumya Swaminathan; Vijayakumar Velu; Barbara Shacklett; Ujjwal Neogi; Luke Elizabeth Hanna
Journal:  Microbiol Spectr       Date:  2021-10-27
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.